Windward Bio raises $225 million in IPO and placement
Windward Bio’s $225 million IPO-and-placement financing funds the Phase 3 portion of WIN378’s asthma trial and mid-stage COPD and atopic dermatitis studies for WIN027 through 2029.
TAG V-8592 · 738 words on the filing

Summary of findings
- $225 million raised: $175 million from the IPO and $50 million from Sanofi’s private placement.
- WIN378 aims for six-month dosing, with two pivotal asthma studies and preliminary data in the first half of 2029.
- WIN027 showed an 84-day half-life in Phase 1 and is designed for three-month dosing.
- Cash stood at $207.3 million at June-end, with runway into the first half of 2029.
- WIN378’s asthma and COPD studies require $217.5 million to $227.5 million.
Windward Bio raised $225 million through its IPO and a Sanofi private placement, with proceeds directed to two long-acting antibody programs in asthma, COPD and atopic dermatitis.
The Basel-based company priced nearly 10.3 million shares at $17, the midpoint of its targeted range, generating $175 million.
Sanofi bought shares and pre-funded warrants at the IPO price in a $50 million private placement. Shares began trading Friday on Nasdaq under “WWB.”
Why does Windward see an opening in established markets?
Windward’s initial indications are asthma, COPD and atopic dermatitis. Biologics are already broadly available in all three, yet the company said use among eligible patients remains relatively low because of inadequate efficacy and frequent injections.
“We believe there is potential for the biologic treatment rate to increase in asthma, COPD, and atopic dermatitis over time as more treatments become available, efficacy and dosing convenience standards improve, and treatments are indicated for more sub-populations of patients,” Windward said in the IPO filing.
What must WIN378 prove?
WIN378 is a long-acting antibody against TSLP, the validated target behind the blockbuster Tezspire, an Amgen and AstraZeneca asthma antibody injected monthly. Windward says WIN378 blocks TSLP more potently and is designed for dosing every six months. The company licensed WIN378 from Sichuan Kelun-Biotech Biopharmaceutical and Harbour BioMed and holds global rights outside certain Asian markets.
WIN378 has entered the Phase 3 portion of a Phase 2/3 trial in severe, uncontrolled asthma. The first of two pivotal studies started in September; the second is due to enroll patients in the first half of 2027. Preliminary data from both are expected in the first half of 2029.
A Phase 2 study in COPD is ongoing, with preliminary results expected in the second half of next year. A pre-planned interim analysis showed a half-life of up to 75 days and improvement in respiratory measures and blood biomarkers correlated with asthma exacerbations.
Windward said WIN378 had been well tolerated, with no reports of treatment-related adverse events and low injection-site reaction rates.
Windward identified Generate Biomedicines’ GB0895 and GSK’s GSK5784283, also known as felcorekibart, as its closest clinical-stage competitors. Both target TSLP with six-month dosing. Upstream Bio and Uniquity Bio are also developing long-acting anti-TSLP antibodies, while AbbVie entered the group through its recent acquisition of Apogee Therapeutics.
Can WIN027 widen the treatment mechanism?
WIN027 blocks TSLP and IL-13 with one long-acting antibody, a dual approach Windward says should deliver deeper and more durable disease control than targeting either pathway alone. It is designed for dosing every three months. Windward licensed global rights outside Greater China from Qyuns Therapeutics.
A Phase 1 study in healthy volunteers is ongoing. Results so far show an 84-day half-life, low immunogenicity and a low rate of injection-site reactions. A Phase 2b study in COPD and a Phase 2 study in atopic dermatitis are due to begin enrollment in the first half of 2027.
What does the financing change for the pipeline?
At the end of June, Windward reported $207.3 million in cash. It expects that balance, combined with the IPO and placement proceeds, to fund operations into the first half of 2029, when preliminary data from the WIN378 asthma studies are due.
Since inception, Windward had raised $310 million as a private company, most recently through a $165 million Series B in May. OrbiMed led the financing, which Windward described as a crossover round.
Novo Holdings was the largest shareholder before the IPO and placement at 13.4%, followed by OrbiMed at 12.8%.
Windward has allocated:
- $217.5 million to $227.5 million to complete WIN378’s Phase 2/3 asthma trial and Phase 2 COPD study.
- $80 million to $85 million for WIN027’s planned Phase 2b COPD test and Phase 2 atopic dermatitis study.
- $5 million to $10 million to advance preclinical bispecific programs through research that could support investigational new drug applications.
The financing removes near-term funding pressure through the first asthma data in 2029; it does not remove the clinical burden. WIN378 still has to translate longer intervals between injections and stronger TSLP blockade into clinical benefit, while WIN027 must show whether combined TSLP and IL-13 blockade produces deeper, durable control in COPD and atopic dermatitis.
The first-half-2029 WIN378 asthma readout will test the central six-month dosing thesis.
via globenewswire.com (Original)
More from Olivia Hart
Show full bio
Senior reporter covering money, funding and market shifts around global pharmaceutical industry at PharmInsider.
13 articles
Linked filings
- K-7275
- V-5496
- V-7932
- K-2547
- K-8919